Appointments

216.444.KIDS (5437)

Request an Appointment

Questions

800.223.2273

Contact us with Questions

Expand Content

Cancer Clinical Trials

The cure rate for childhood cancer has improved greatly in the last two decades largely because of treatment in national clinical trials.

Clinical trials are designed to test new and potentially better treatments against those treatments considered standard in the hope of finding better treatments for childhood cancer and related disorders. Clinical trials are ongoing in most parts of the country for most types of childhood cancer. The good news is that Children's Oncology Group clinical trials are closely overseen by a data monitoring committee. As soon as one treatment is found to work more effectively than another, the treating physicians are notified immediately, and your child's treatment changed immediately, if necessary.

The following is a list of open clinical trials available at Children's Department of Pediatric Hematology/Oncology as of May 2007. This list is constantly changing, so please contact Principal Investigator Dr. Megan Burke at 216.444.5517 to discuss your child's needs with us.

Pediatric Hematology Oncology Clinical Trials

Bone Marrow Transplant
  • FHCRC 2064 Pediatric Nonmyeloablative Hematopoietic Cell Transplantation for Patients with Fanconi Anemia Using Alternative Marrow Donors: A Phase I/II Dose-Finding Study
  • FHCRC 2007 Pediatric Hematopoietic cell transplantation for treatment of patients with primary immunodeficiencies and other nonmalignant inherited disorders using low-dose TBI and fludarabine with or without Campath
Brain Tumor Trials
  • ACNS0121 A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma, and Observation for Completely Resected Differentiated, Supratentorial Ependymoma
  • ACNS0122 A Phase II Study to Assess the Ability of Neoadjuvant Chemotherapy +/- Second-Look Surgery to Eliminate All Measurable Disease Prior to Radiotherapy for NGGCT
  • ACNS02B3 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
  • ACNS0232 Radiotherapy Alone vs. Chemotherapy Followed By Response-based Radiotherapy For Newly Diagnosed Primary CNS Germinoma
  • ACNS0223 Pilot Study Using Carboplatin, Vincristine and Temozolomide for Children Less Than or Equal to 10 Years of Age with Progressive/Symptomatic Low-Grade Gliomas
  • ACNS0224 A Phase I/II Study of Topotecan with G-CSF and Radiation Therapy in Children with Malignant Intrinsic Pontine Brainstem Gliomas of Childhood
  • ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced-Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard-Risk Medulloblastoma:  A Phase III Double-Randomized Trial
  • ACNS0423 Concurrent Radiation and Temozolomide Followed By Temozolomide and Lomustine in the Treatment of High-Grade Gliomas
  • ADVL0524 A Phase II Study of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults with Refractory Solid Tumors
  • IRB 5181 Central Nervous System Atypical Teratoid/Rhabdoid Tumor Registry
  • Head Start III IRB #7734 Dose-Intensive Chemotherapy for Children Less Than 10 Years of Age Newly Diagnosed With Malignant Brain Tumors
  • IRB 6140 Chemo/Radiation Therapy for CNS Atypical Teratoid/Rhabdoid Tumor
Hepatoblastoma Trials
  • COG-P9645 Intergroup Protocol for Treatment of Children With Hepatoblastoma
Hodgkin Disease Trials
  • AHOD0031 A Phase III Group-Wide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin's Disease
  • AHOD0321 A Phase II Study of Weekly Gemcitabine and Vinorelbine in Children With Recurrent or Refractory Hodgkin Disease
  • AHOD03P1 Treatment of Children with Newly Diagnosed Low-Stage Lymphocyte-Predominant Hodgkin Disease (LPHD)
  • AHOD04B1 Hodgkin Disease Banking Study
Leukemia, Acute Lymphoblastic Leukemia Trials
  • A5971 A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma 
  • AALL0232 High-Risk B-Precursor Acute Lymphoblastic Leukemia
  • AALL02P2 Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1>/= 18months)
  • AALL0331 Standard Risk B-Precursor Acute Lymphoblastic Leukemia
  • AALL03B1 Classification of Acute Lymphoblastic Leukemia
  • AALL0434 Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL)
  • AALL05B1 A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
  • ASCT0521 Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
  • IRB 07-086 Use of Erwinia Asparaginase for Pediatric Patients
Leukemia, Acute Myelogenic Leukemia Trials
  • A5971 A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma
  • AAML0531 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
  • ASCT0521 Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Lymphoma Trials
  • ANHL0131 A Phase III Trial of Treatment of Advanced State Anaplastic Large Cell Lymphoma with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine
  • ANHL0221 A Phase II Study of the Combination of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults with CD20 Positive Post-Transplant Lymphoproliferative Disease (PTLD) following Solid Organ Transplantation (SOT)
  • ANHL04B1 Rare and Cutaneous Non-Hodgkin's Lymphoma Registry
  • ASCT0521 Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Neuroblastoma Trials
  • ADVL0524 A Phase II Study of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults with Refractory Solid Tumors
  • ANBL00B1 Neuroblastoma Biology Studies
  • ANBL00P2 Perinatal Neuroblastoma: Expectant Observation. A Children's Oncology Group Pilot Study
  • ANBL0032 Phase III Randomized Study of Chimeric Anti-GD2 in High-Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
  • ANBL0322 A Phase II study of hu14.18-IL2 (BB-IND-9728) in Children with Recurrent or Refractory Neuroblastoma
  • ANBL0421 A Phase II Study of Irinotecan + Temozolomide in Children with Recurrent Neuroblastoma
Osteosarcoma Trials
  • ADVL0524 A Phase II Study of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults with Refractory Solid Tumors
  • AOST0221 A Phase II Study of Aerosolized GM-CSF (NSC #613795, IND #11042) in Patients with First Pulmonary Recurrence of Osteosarcoma
  • AOST0331 A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy
  • P9851 Osteosarcoma Biology Protocol:  Companion to Groupwide Therapeutic Studies
Pediatric Solid Tumor Trials
  • ADVL0524 A Phase II Study of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults with Refractory Solid Tumors
  • AEWS02B1 A Groupwide Biology and Banking Study for Ewing Sarcoma
  • AEWS02P1 A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination with Standard Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors
  • AEWS0331 European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)
  • AEWS0621A Phase II Trial Modulating EWS/FLI with Cytarabine for Children and Young Adults with Relapsed Ewing Sarcoma
  • AGCT0132 A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors
  • AREN03B2 Renal Tumors Classification, Biology, and Banking Study
  • ARET0332  A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy
  • ARST0321 A Phase II Study of Sulindac and Tamoxifen in Patients with Desmoid Tumors That Are Recurrent or Not Amenable to Standard Therapy
  • ARST0531 Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
  • ABTR01B1 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
  • CCG-0923 A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose
  • D9902 A COG Soft Tissue Sarcoma Biology and Banking Protocol
Rhabdomyosarcoma Trials
  • ADVL0524 A Phase II Study of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults with Refractory Solid Tumors
  • ARST0321 A Phase II Study of Sulindac and Tamoxifen in Patients with Desmoid Tumors That Are Recurrent or Not Amenable to Standard Therapy
  • ARST0331 Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
  • ARST0431 Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma
  • ARST0531 Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
  • D9902 A COG Soft Tissue Sarcoma Biology and Banking Protocol
Wilms Tumor Trials
  • ADVL0524 A Phase II Study of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults with Refractory Solid Tumors
  • CCG-4941L National Wilms Tumor Late Effects Study
Other Trials
  • GNTM 1Z12 Defibrotide for patients with hepatic veno-occlusive disease (VOD): A treatment IND study (Under CFR 312.34)
  • IRB 5507 Severe Chronic Neutropenia International Registry
  • IRB 6462 Gaucher Registry
  • IRB 6527 Fabry Registry
  • IRB 7295 Mucopolysaccharidosis I (MPS I) Registry
  • ASCT0521 Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
  • IRB 07-086 Use of Erwinia Asparaginase for Pediatric Patients